AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 5 - (NewsRx.com & NewsRx.net) -- Prostaglandin EP[subscript]2 receptor mediates endometrial cancer angiogenesis.
"Prostaglandin (PG) E-2 E-series prostanoid-2 (EP[subscript]2) receptor is elevated in numerous carcinomas including the endometrium and has been implicated in mediating the effects of PGE[subscript]2 on vascular function. In this study, we investigated the intracellular signaling pathways that are activated by the EP[subscript]2 receptor and their role in regulation of the expression of vascular endothelial growth factor in endometrial adenocarcinoma (Ishikawa) cells," scientists in Scotland report.
"Ishikawa cells were stably transfected with EP2 receptor cDNA in the sense or antisense directions. Treatment of Ishikawa cells with PGE[subscript]2 rapidly induced transactivation of the epidermal growth factor receptor (EGFR) and activation of ERK1/2 via the EP[subscript]2 receptor," stated K.J. Sales and colleagues, University of Edinburgh, Academic Center.
"Preincubation of cells with chemical inhibitors of protein kinase A, c-Src, and EGFR kinase abolished the EP[subscript]2-induced activation of EGFR and ERK1/2. PGE[subscript]2 signaling via the EP[subscript]2 receptor also promoted the mRNA expression and secretion of vascular endothelial growth factor protein in Ishikawa cells. This effect was inhibited by preincubation with chemical inhibitors of EGFR kinase, ERK1/2 signaling, and small inhibitory RNA ...
Source: HighBeam Research, Prostaglandin EP[subscript]2 receptor mediates endometrial cancer...